AKT1 and cancer: Together with the observation regarding enhanced repression of Src/PI3K/AKT by Rapamycin in multiple NSCLC cell lines, our results suggested that the synergistic anti-cancer effect of Dasatinib and Rapamycin was probably due to the inhibition of PI3K/Akt signaling transduction.